Apixaban Intermediate (CAS 1267610-26-3)
Google Keywords: Apixaban Intermediate, CAS 1267610-26-3, Anticoagulant API Synthesis, GMP Pharmaceutical Intermediates, Direct Oral Anticoagulant (DOAC) Production
🌟 Product Overview
Apixaban Intermediate (CAS 1267610-26-3) is a high-purity chemical intermediate essential for synthesizing Apixaban, a leading direct oral anticoagulant (DOAC) used to prevent stroke and systemic embolism in patients with atrial fibrillation. Designed for scalable API manufacturing, this intermediate ensures robust process control and regulatory compliance.
Primary Function: Enables precise synthesis of Apixaban with minimized impurities and optimized yields.
Applications: DOAC production, cardiovascular drug development, and generic formulations.
✅ Key Advantages
🔹 Ultra-High Purity | ≥99.5% (HPLC/GC verified) | Residual solvents <20 ppm.
🔹 Process Stability | Batch-to-batch consistency validated for large-scale API production.
🔹 Regulatory Alignment | Complies with ICH Q11, USP/EP standards, and GMP guidelines.
🧪 Applications
Anticoagulant APIs: Core component in Apixaban synthesis for atrial fibrillation and thrombosis treatment.
Clinical Trials: Supports preclinical and phase I-III studies for novel DOAC formulations.
Generic Drug Manufacturing: Critical for post-patent API commercialization.
📜 Quality Assurance
Testing Methods: HPLC, GC, NMR, and LC-MS for identity, purity, and impurity profiling.
Standards: Meets USP <1086>, EP 10.0, and ISO 9001:2015 quality systems.
📈 Market Trends
The global oral anticoagulants market is projected to reach $27.4 billion by 2030 (CAGR 6.5%), driven by rising prevalence of atrial fibrillation and venous thromboembolism. Apixaban intermediates are pivotal in meeting demand for safer, non-vitamin K antagonist therapies.
Empower your anticoagulant API production with Apixaban Intermediate – unparalleled purity, compliance, and scalability for life-saving therapeutics.
China
